Compare Danaher Corporation (DHR) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Infosys Limited — how do they compare? Danaher Corporation trades at $219.85 (market cap $152.87B), while Infosys Limited trades at $10.77 (market cap $41.74B). The key difference: Danaher Corporation is far larger — about 3.7× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Infosys Limited for 27 Days on average.
| DHR | INFY | |
|---|---|---|
Market Cap | $152.87B | $41.74B |
Volume | 5,228,698 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $242.05 | $20.22 |
52-Week Low | $161.91 | $10.49 |
Typical Hold Time | 69 Days | 27 Days |
Enterprise Value | $175.08B | $39.48B |
Dividend Yield | 0.74% | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
